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Objective: Myeloid neoplasms are heterogeneous diseases that are more  incident in the
elderly. The goals of this study were to aggregate a geriatric approach to the patient assess-
ment, to show the impact of gender, age, hemoglobin concentration and comorbidities on
the functionality of elderly with myeloid neoplasms and to better understand how the
instruments of functional assessment work according to the aggressiveness of the disease.
Methods: Elderly patients (≥60 years old) with myeloid neoplasms were assessed using
the  Karnofsky scale, Eastern Cooperative Oncologic Group scale, and basic and instru-
mental activities of daily living scales. The hematopoietic cell transplantation-comorbidity
index assessed the comorbidities. A mixed logistical regression model was ﬁtted to esti-
mate the impact of gender, age, hemoglobin concentration and the hematopoietic cell
transplantation-comorbidity index on patients’ functionality.
Results: Eighty-two patients with a mean age of 72.8 years (range: 60–92 years) were evalu-
ated.  Eighty percent had good Karnofsky and Eastern Cooperative Oncologic Group scales
and 39% were independent according to the daily living activity scales. All of the patients
with poor Karnofsky and Eastern Cooperative Oncologic Group scales were classiﬁed as
dependent by the daily living activity scales. The mixed logistic regression models showed
that age, gender, hemoglobin concentration and the comorbidity index impacted on the
daily living activity scales. Karnofsky and Eastern Cooperative Oncologic Group scales were
affected by hemoglobin and the comorbidity index. The model hypothesized the hemoglobin
concentration at which there was a higher risk of poor Karnofsky and Eastern Cooperative
Oncologic Group scales. This hemoglobin concentration depended on comorbidities and on
the  aggressiveness of the myeloid neoplasm.
Conclusion: The geriatric approach improved the sensitivity and speciﬁcity of the patients’
assessment. Hemoglobin concentration associated to the risk of poor Karnofsky and Eastern
Cooperative Oncologic Group scales depended on the comorbidity score and on the disease
aggressiveness. The Karnofsky and Eastern Cooperative Oncologic Group scales had higher
sensitivity in patients with more aggressive diseases.© 2015 Associac¸ão Bra
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Introduction
Myeloid neoplasms (MN) are a group of heterogeneous dis-
eases that include myeloproliferative neoplasms (MPN),
myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML). All these diagnosis are more incident
and prevalent in elderly individuals.
This group of diseases includes from indolent entities
such as polycythemia vera and essential thrombocythemia,
to aggressive diseases, such as AML  and MDS  with excess
of blasts. Chronic myeloid leukemia and myeloﬁbrosis have
some risk to evolve aggressively.1
The management of older individuals with MN  takes into
account characteristics related to the patient and to the
disease.2–6 The chronological age, the performance status (PS)
and the comorbidity score are patient-related variables that
are considered during treatment decision making of elderly
individuals.7–9
The PS assessment is carried out using the Karnofsky
Performance Scale10 (KPS) or by the Eastern Cooperative Onco-
logic Group11 (ECOG) scale. However, over the last thirty years,
several studies have demonstrated the low sensitivity of these
instruments to evaluate function in older individuals with
cancer.12–14 Thus, it has been recommended to aggregate geri-
atric tools to the PS assessment.
The major clinical challenge in the management of all
myeloid neoplasms is the treatment of AML in older patients.
Depending on the clinical and functional reserve of the
patient, the therapeutic approach may be excessively toxic.2
Thus, it is very helpful to distinguish the impact of the aging
process separated from the impact of the disease.15
The objectives of this study were to assess the functional-
ity of elderly patients with MN  aggregating the basic activity16
(ADL) and instrumental activity17 (IADL) of daily living scales
to the KPS and ECOG and to evaluate the impact of gender,
age, hemoglobin (Hb) concentration and comorbidity score on
the functionality of these patients. A third objective was to
design a model to show how functional assessment instru-
ments work in respect to the aggressiveness of the disease.
Methods
Elderly patients (≥60 years old) with MN  followed at the Hema-
tologic Outpatient Clinic of the Universidade Federal de São
Paulo, (UNIFESP) were included in this study.
Diagnoses were based on the World Health Organization
(WHO) Classiﬁcation of tumors of hematopoietic and lym-
phoid tissues18 using the analysis of peripheral blood and
bone marrow smears, the histology of bone marrow biopsy,
and immunophenotypic, cytogenetic and molecular studies.
The patient’s functional evaluation was performed by
a hematologist just before the clinical consultation and
included PS assessed employing the KPS and ECOG scales
and functional status with the ADL and IADL scales. Comor-
bidities were evaluated according to the hematopoietic cell
transplantation-comorbidity index (HCT-CI) developed by Sor-
ror in 2005.19 2 0 1 5;3  7(2):109–114
The Hb concentration was measured by an automated
technique employing a multichannel hematology analyzer
(CELL-DYN Ruby, Abbott Diagnostic Division) using a blood
sample taken before the consultation.
Patients with transfusion positive status received red blood
cells prior to the determination of the Hb concentration in
the month preceding the functional assessment. The deci-
sion to transfuse was based on the drop in Hb and its related
symptoms. Demographic and clinical data were obtained from
medical records.
The study was approved by Research Ethics Committee of
UNIFESP (#0262/10) and the procedures undertaken were in
accordance with the Declaration of Helsinki of 1975, revised
in 2008.20 All patients signed informed consent forms.
Statistical  analysis
Analyses of means of age and Hb concentration were per-
formed using Student’s t test or ANOVA with Tukey’s test.
The frequencies of categorical variables were evaluated with
Fisher’s exact test.
Two mixed logistic regression models were ﬁtted to assess
the impact of gender, age, HCT-CI and Hb concentration on PS,
dichotomized as good (KPS ≥ 80% and ECOG < 2) or poor, and
on functional status, as independent or dependent (need help
in at least one daily task).
Generally, mixed models consider the information hierar-
chically structured at the unit and cluster levels. These cluster
levels result from a grouping process outlined by character-
istics shared by the units. Moreover, in mixed models the
assumption of independence is violated, because there is a
correlation between the units that belong to the same cluster.
Random effects are included on considering this fact.
Mixed models incorporate these random effects and
estimate them for each group. Therefore, the groups are repre-
sented by random effects and the variability across the groups
is described by the intercept or the slope variability. The mixed
model belongs to generalized linear mixed models (MLGM),
which is an extension of generalized linear models (GLM).21,22
Statistical analysis was performed using R statistics (v2.15)
and the Statistical Package for the Social Sciences (SPSS – v18).
Results
Eighty-two patients, 40 men  and 42 women, with a mean age
of 72.8 years old (range: 60–92 years), were evaluated. Table 1
shows the descriptive statistics of the demographic data, func-
tionality scores and comorbidity indices.
Of the ﬁfteen patients with polycythemia vera (PV) and
six with essential thrombocythemia (ET), 73% and 50%
were JAKV617F positive, respectively. Ninety percent of these
patients were taking hydroxycarbamide to control the disease.
All the nine patients who had chronic myeloid leukemia
(CML) were in the chronic phase; seven were taking imatinib
mesylate and four were in molecular remission.Nine out of 25 patients with myeloﬁbrosis (MF) were in
the sclerotic phase, two in blastic transformation and the
remaining 14 were in the cellular phase. Eleven patients were
JAKV617F positive and 80% were taking hydroxycarbamide.
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Table 1 – Age, gender, functionality scores and comorbidity indices stratiﬁed by myeloid neoplasm.
MN (n) Age (years)a Gender (n = male) KPSb ECOGb ADLb IADLb HCT-CI (n)
Index 0 Index 1–2 Index ≥ 3
PV (15) 70.8 (60–83; 7.5) 10 100
(70–100)
0
(0–1)
6
(5–6)
27
(11–27)
6  5 4
ET (6) 72.3 (63–83; 8.2) 1 85
(60–100)
0.5
(0–2)
5.5
(5–6)
26.5
(18–27)
1  3 2
CML (9) 74.9 (63–88; 7.6) 3 90
(60–100)
0
(0–1)
6
(6–6)
26
(14–27)
6  3 0
MF (25) 72.7 (61–92; 8.5) 14 90
(40–100)
1
(0–2)
6
(4–6)
27
(11–27)
15  2 8
MDS (17) 74.4 (64–90; 8.2) 6 90
(40–100)
1
(0–3)
6
(3–6)
25
(12–27)
5  7 5
AML (10) 71.9 (61–84; 7.5) 6 70
(30–100)
2
(0–3)
5.5
(1–6)
16.5
(9–27)
5  4 1
TOTAL (82) 72.8 (60–92; 7.9) 40 90
(30–100)
0
(0–3)
6
(1–6)
26
(9–27)
38  24 20
MN: myeloid neoplasm; PV: polycythemia vera; ET: essential thrombocythemia; CML: chronic myeloid leukemia; MF: myeloﬁbrosis; MDS:
myelodysplastic syndromes; AML: acute myeloid leukemia; KPS: Karnofsky performance scale; ECOG: Eastern Cooperative Oncology Group
scale; ADL: basic activities of daily living scale; IADL: instrumental activities of daily living scale; HCT-CI: hematopoietic cell transplantation-
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a Mean (min-max; standard deviation).
b Median.
Two out of 17 patients with MDS  had refractory anemia with
xcess blasts (RAEB), one had refractory anemia (RA), four had
efractory anemia with ringed sideroblasts (RARS), two had
solated del(5q) and six had refractory cytopenia with multi-
ineage dysplasia (RCMD). Two MDS  patients were treated with
ypomethylating more  than six months prior to the functional
valuation. In addition, two patients were on the thalido-
ide protocol23 and two had received this drug more  than
ix months prior to the functional assessment. Two patients
ith chronic myelomonocytic leukemia were included in the
DS  group.
Six out of ten patients with AML  had received chemother-
py, on average, 86 days before the evaluation and were in
ematological remission at the moment of the functional
ssessment. There were seven AML  not otherwise speciﬁed,
wo with myelodysplasia-related changes and one with recur-
ent genetic abnormalities [t(8;21)].
The Hb concentration, the incidence of anemia and the
ransfusion status were different across the MN types (Table 2).
n view of this evidence, patients were divided into: Group I (PV,
T and CML), II (MF) and III (MDS and AML).
Table 2 – Grouping of patients based on mean Hb concentration
Group I 
PV (n = 15) ET (n = 6) CML (n =
Hb (g/dL) 14.8a
(12.1–16.8;
1.51)
13.55a
(11.8–15.1;
1.31)
12.13
(11.0–13
0.78)
Tx
Yes  0 0 0 
No 15 6 9 
PV: polycythemia vera; ET: essential thrombocythemia; CML: chronic mye
AML: acute myeloid leukemia; Hb: hemoglobin concentration; TX: red cell
a Identify signiﬁcant differences (ANOVA with Tukey’s test).
b Fisher’s test.The Hb concentration was higher in patients with good
PS (KPS/ECOG) than in patients with poor PS (p-value < 0.01).
Likewise, the Hb concentration was higher in independent
patients (ADL/IADL) than in those with dependence in daily
tasks (p-value < 0.01). Patients with some dependence in daily
activities were older than those with no dependence in
ADL/IADL (p-value < 0.01). There was no signiﬁcant difference
in age between patients with good and poor PS. Women had
higher ADL/IADL dependence scores than men  (p-value < 0.01).
Eighty percent (n = 65) of the patients had good PS, however
50% of these patients (n = 33) had some dependence in daily
activities. Seventeen patients had poor PS and all of them were
dependent for some daily activities (Table 3).
There were patients with good PS and independent; others
with good PS and dependent and, ﬁnally, there were patients
with poor PS, all of who had some dependence for daily tasks
(Table 4).
Table 4 shows that when compared to Groups I and II,
Group III (MDS and AML) had a higher number of patients
with poor PS and lower number of patients with good PS but
dependent.
 and transfusion demand.
Group II Group III p-value
 9) MF (n = 25) MDS (n = 17) AML (n = 10)
.2;
11.33a
(3.5–15.1;
2.90)
9.99a
(6.3–12.9;
1.54)
9.66a
(5.9–13.0;
2.36)
<0.01a
7 7 8 <0.001b
18 10 2
loid leukemia; MF: myeloﬁbrosis; MDS: myelodysplastic syndromes;
 transfusion during 30 days before functional assessment.
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Table 3 – Distribution of patients by performance and
functional status.
Functional status Performance status Total
Good Poor
Independent 32 (50%) 0 32
Dependent 33 (50%) 17 (100%) 50
Total 65 17 82
Good performance status: KPS ≥ 80% and ECOG < 2; Independent: no
dependence for ADL and IADL.
Table 4 – Distribution of patients by groups and
functionality.
Groups (n) Good performance
status
Poor  performance
status
Independent Dependent Dependent
I – PV + ET +
CML (30)
13 14 3
II – MF (25) 13 11 1
III – MDS +
AML (27)
6 8 13
TOTAL (82) ap = 0.001
Good performance Status: KPS ≥ 80% and ECOG < 2; Independent:
no dependence in ADL and IADL.
PV: polycythemia vera; ET: essential thrombocythemia; CML:
chronic myeloid leukemia; MF: myeloﬁbrosis; MDS: myelodysplastic
important clinical value is that this critical Hb concentrationsyndrome; AML: acute myeloid leukemia.
a Fisher’s exact test.
A mixed logistic regression model was applied to explain
PS (by KPS and ECOG scales) which was inﬂuenced by Hb con-
centration (p-value = 0.019) and HCT-CI (p-value = 0.07). Gender
(p-value = 0.22) and age (p-value = 0.77) did not impact on the
PS. Thus, the ﬁnal logistic model included only the Hb con-
centration and HCT-CI. The variance of the random effect of
grouping was 1.18. The random effects (intercepts) in Groups
I, II, and III were 0.27, −1.15 and 1.06, respectively.
The hypothetical Hb concentrations at which there were
increased risks of having poor PS are reported in Table 5. These
Hb concentrations depended on the group (I, II or III) and on the
HCT-CI (0, 1, 2 or ≥3). This model had an area under the receiver
operating characteristic (ROC) curve of 0.85, with sensitivity of
76% and speciﬁcity of 75%.
A mixed logistic regression also demonstrated the impact
of age (p-value = 0.006), gender (p-value = 0.002), comorbidities
Table 5 – The hypothetical hemoglobin concentration for poor p
transplantation-comorbidity index of patients with myeloid ne
Groups HCT-CI
0 1 
I – PV/ET/CML 9.53 10.52 
II – MF 5.61 6.61 
III – MDS/AML 11.71 12.70 
PV: polycythemia vera; ET: essential thrombocythemia; CML: chronic mye
AML: acute myeloid leukemia; HCT-CI: hematopoietic cell transplantation 2 0 1 5;3  7(2):109–114
(p-value = 0.014) and Hb concentration (p-value = 0.058) on the
functional status (by ADL and IADL). The variance of random
effect of grouping was 0.09. The random effects (intercepts) in
Groups I, II, and III were 0.07, −0.23 and 0.16, respectively.
Considering similar conditions of comorbidities, Hb and
age, female patients were more  likely to be dependent in some
daily activity than the male individuals. Older age and higher
HCT-CI and lower Hb concentration increased the likelihood
of functional dependence. This model indicated a value of 0.84
for the area under the ROC curve, with sensitivity of 74% and
speciﬁcity of 72%, indicating good predictive power.
Discussion
This study showed that the sensitivity of the functional
assessment of these elderly patients with MN  was increased
by adding ADL and IADL to the KPS/ECOG. This was proven
by the fact that 50% of the patients with good PS had some
dependence in daily activities (Table 3).
On the other hand, the heterogeneity of MN showed that
KPS and ECOG had different sensitivity and speciﬁcity depend-
ing on the clinical context they were applied in. In this study,
these instruments had higher sensitivity and speciﬁcity in
patients with AML and MDS. As illustrated by Table 4, this
group had a low number of individuals with good PS but with
dependence in ADL/IADL, and a high number of patients with
poor PS with some dependence in ADL/IADL.
Here, the characteristics related to each MN  were repre-
sented by the Hb, transfusion demands and the diagnosis of
anemia. All of the other disease-related variables were char-
acterized by the logistic regression model as random effects.
The model ﬁtted in this study incorporated the differences
between the MN as random effects. These characteristics were
related to the pathogenesis and to the treatment of each dis-
ease. Thus, the analysis of the data of Groups I, II and III
was signiﬁcant to the mixed logistic regression model that
detected the impact of these difﬁcult-to-control variables.
In this group of patients the Hb concentration and the HCT-
CI, but not the age or gender, impacted on the PS of elderly
patients with MN as assessed by KPS and ECOG. The mixed
logistic regression ﬁtted a model that hypothesized an Hb con-
centration that was critical to poor PS (Table 5). The mostdepended on the aggressiveness of the MN and on the HCT-CI.
This Hb concentration should not be extrapolated but, as
far as we know, this is the ﬁrst survey that ﬁtted a model which
erformance status and hematopoietic cell
oplasms.
2 ≥3
11.51 12.50 Critical hemoglobin
(g/dL) concentration
for poor performance
status
7.60 8.59
13.69 14.68
loid leukemia; MF: myeloﬁbrosis; MDS: myelodysplastic syndromes;
-comorbidity index.
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ould comprise functional assessment and comorbidity score,
inked by Hb concentration. Thus, it is possible to conclude
hat anemia and HCT-CI impact on the functionality of elderly
ith MN, mainly those with AML  and MDS.
As illustrated by Table 5, Group III has the highest critical Hb
or poor performance. This fact is congruent to the evidence of
igher KPS/ECOG sensitivity in patients with AML/MDS than
n other MN. Thus, KPS and ECOG are more  easily affected by
rops in Hb in Group III compared to Groups I and II.
This evidence may be justiﬁed, in part, by the fact that,
sually, anemia in patients of Groups I and II occurs over
 longer period of time than in those of Group III. Hence,
daptive mechanisms can be triggered over time to better pre-
erve the functional autonomy of patients in Groups I and
I.
Another important aspect to be considered is that
CT-CI is a score speciﬁcally validated in patients with
ML/MDS. As far as we  know, there are few studies assessing
atients with chronic myeloproliferative disorders using this
nstrument.24,25
All these aspects show the necessity for a process that
alidates the hypothetical Hb values that are critical to poor
erformance (Table 5). This process can be designed by com-
aring the results of this model applied to patients with
hronic myeloproliferative disorders using HCT-CI and the
harlson scale,26 for example.
At this time, the Hb values shown in Table 5 should be
ssumed less as the targets to be reached in patients with
N and more  as an alert that drops in Hb affect func-
ionality mainly of patients with AML/MDS and with high
CT-CI.
Functional status assessed employing ADL and IADL was
nﬂuenced by gender, age, Hb and comorbidities. There was
n increasing dependence in daily activities with drops in
b concentration, increases in HCT-CI, advancing age and for
emale patients. This evidence may help healthcare profes-
ionals provide social support better adjusted to the patient’s
eeds.
As a cross-sectional survey, this study was not designed
o analyze other medical procedures. It should be noted that
rognostic scores for MF  and MDS  take into account Hb con-
entration and transfusion requirements. Thus, the model
tted here surely can be better calibrated in a longitudinal type
tudy.
As an observational study, it was very hard to control each
ariable in particular those that comprise the logistic regres-
ion model with multivariate analysis. This study was not
esigned to understand the prognostic value of variables that
ere included. Previous studies pointed out that functionality
as been correlated not only to survival but to the quality of
ife, mainly in elderly patients with MN.27
This paper is the preliminary result of a research aimed at
mproving the assessment of elderly patients with MN.
onclusionshe aggregation of ADL and IADL to the KPS and ECOG
cales improved the sensitivity and speciﬁcity of the func-
ional assessment of elderly with MN, mainly those with AML 1 5;3  7(2):109–114 113
and MDS. Age, gender, Hb and comorbidities affected func-
tional status. However, only comorbidities and Hb impacted
on PS. The model ﬁtted with KPS/ECOG identiﬁed criti-
cal Hb concentrations for poor PS which depends on the
aggressiveness of the MN and on the HCT-CI. Thus anemia
and HCT-CI impacted on the functionality of this group of
patients, mainly those with AML and MDS. Patients with
AML  and MDS were more  sensitive in respect to KPS and
ECOG compared to other patients with less aggressive dis-
eases.
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